Sanofi-Aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced encouraging preliminary results from two Phase 2 studies in advanced ovarian cancer and lung cancer with aflibercept (VEGF Trap) an anti-angiogenic agent targeting Vascular Endothelial Growth Factor. Aflibercept (VEGF Trap) is being developed by Regeneron in collaboration with sanofi-aventis. The companies will present data from the lung cancer study tomorrow. These are the first reported results from a late-stage development program consisting of single-agent studies and planned Phase 3 trials in combination with common chemotherapy regimens in several different solid tumor types. The presentation reviewing the advanced ovarian cancer trial and the poster describing the lung cancer trial will be available on the Regeneron website (www.regeneron.com on the Events page, under the Investor Relations heading) later, after they are presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
